BlackRock Boosts Evolus Stake to 7.0% as of Dec 31, 2023
Ticker: EOLS · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1570562
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, stake-disclosure
TL;DR
**BlackRock now owns 7.0% of Evolus, a bullish sign for the stock.**
AI Summary
BlackRock Inc., a major investment firm, reported its holdings in Evolus, Inc. (pharmaceutical preparations) as of December 31, 2023. BlackRock now beneficially owns 4,374,138 shares of Evolus's Common Stock, representing 7.0% of the company. This matters to investors because it signals BlackRock's continued significant interest in Evolus, potentially indicating confidence in the company's future performance and stability, which could influence other institutional and retail investors.
Why It Matters
A large institutional investor like BlackRock increasing its stake can be seen as a vote of confidence in Evolus, potentially attracting more investment and stabilizing the stock price.
Risk Assessment
Risk Level: low — This filing indicates a large institutional investor's significant, but passive, stake, which generally reduces volatility rather than increasing risk.
Analyst Insight
A smart investor would view BlackRock's substantial, passive stake as a positive signal, suggesting stability and potential long-term value in Evolus, and might consider further research into Evolus's fundamentals.
Key Numbers
- 4,374,138 — Shares Owned (Total shares of Evolus Common Stock beneficially owned by BlackRock Inc.)
- 7.0% — Ownership Percentage (Percentage of Evolus's Common Stock beneficially owned by BlackRock Inc.)
Key Players & Entities
- BlackRock Inc. (company) — reporting person, investment firm
- Evolus, Inc. (company) — subject company, pharmaceutical preparations
- 4,374,138 (dollar_amount) — number of shares beneficially owned by BlackRock
- 7.0% (dollar_amount) — percentage of Evolus's Common Stock owned by BlackRock
- December 31, 2023 (person) — date of event requiring the filing
Forward-Looking Statements
- BlackRock will maintain a significant, passive stake in Evolus for the foreseeable future. (BlackRock Inc.) — high confidence, target: December 31, 2024
FAQ
What is the purpose of an SC 13G filing?
An SC 13G filing is used by passive investors who own more than 5% of a company's stock to disclose their holdings to the SEC, indicating they do not intend to influence or control the company's management or policies. This specific filing by BlackRock Inc. is under Rule 13d-1(b).
Which company is the subject of this SC 13G filing?
The subject company of this SC 13G filing is Evolus, Inc., which operates in the pharmaceutical preparations industry (SIC 2834).
Who is the reporting person in this SC 13G filing?
The reporting person in this SC 13G filing is BlackRock Inc., a major investment management firm (SIC 6211).
As of what date were the reported holdings accurate?
The reported holdings in Evolus, Inc. by BlackRock Inc. were accurate as of December 31, 2023, which is the 'Date of Event Which Requires Filing of this Statement'.
What type of securities does BlackRock Inc. own in Evolus, Inc.?
BlackRock Inc. owns 'Common Stock' of Evolus, Inc., identified by the CUSIP Number 30052C107.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 by December 31, 2023 regarding Evolus, Inc. (EOLS).